

Micardis HCT is a prescription medication used to treat high blood pressure (hypertension) in adults. It contains 2 active ingredients: telmisartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). It is not indicated for the initial treatment of hypertension. It is generally used when blood pressure is not adequately controlled with a single medication.
Below is a quick overview of important facts for patients and caregivers:
| Brand Name | Micardis HCT |
|---|---|
| Active Ingredient | Telmisartan/hydrochlorothiazide |
| Strengths | 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg |
| Drug Class | ARB + Thiazide diuretic |
| Primary Use | Treatment of hypertension in adults |
| Dosage Form | Oral tablet |
| Prescription Required | Yes |
| Boxed Warning | Fetal Toxicity: Discontinue when pregnancy is detected due to the risk of injury or death to the developing fetus |
| Storage | Store at 68°F to 77°F (20°C to 25°C); keep in original blister until use |
← Swipe to see more →
Micardis HCT is prescribed to treat high blood pressure (hypertension) in adults:
Warning: Fetal Toxicity
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy can lower fetal renal function and increase the risk of fetal and neonatal morbidity and death. When pregnancy is detected, discontinue Micardis HCT tablets as soon as possible. Thiazide diuretics cross the placental barrier and may cause fetal or neonatal jaundice and thrombocytopenia.
Micardis HCT combines two medications with antihypertensive effects:
By combining these two actions, the medication achieves greater blood pressure reduction than either drug alone.
Always follow your healthcare provider’s instructions. General guidelines include:
Do not stop taking Micardis HCT without consulting your healthcare provider.
Micardis HCT dosing depends on prior treatment and blood pressure response.
| Clinical Situation | Recommended Dose |
|---|---|
| Blood pressure not controlled on telmisartan 80 mg alone | 80 mg/12.5 mg once daily |
| Blood pressure not controlled on hydrochlorothiazide 25 mg alone, or controlled but with hypokalemia | 80 mg/12.5 mg once daily |
| If additional control is needed after 2-4 weeks | May titrate up to 160 mg/25 mg once daily, as directed by a healthcare provider |
| Patients are already titrated to the individual components | May switch to equivalent Micardis HCT combination |
← Swipe to see more →
Hepatic Impairment:
Important administration instructions:
There is limited clinical information about overdose cases of Micardis HCT. Symptoms may reflect the effects of either component.
Telmisartan is not dialyzable. The extent to which hydrochlorothiazide is removed by hemodialysis has not been established. If an overdose is suspected, seek immediate emergency medical help or contact a poison control center.
The Micardis HCT tablets may cause side effects, some of which can be serious.
Commonly reported Micardis HCT side effects are listed below:
This medication may cause serious adverse reactions. Seek medical attention if you experience any of the following:
This is not a complete list of side effects. Contact your healthcare provider for medical advice about adverse reactions. You may report side effects to the FDA at 1-800-FDA-1088 or visit MedWatch.
While using this medication, the following warnings should be considered:
Pregnancy: Micardis HCT tablets can cause fetal harm when used during the second and third trimesters. Exposure to drugs that act on the renin-angiotensin system may result in reduced fetal kidney function, low amniotic fluid levels (oligohydramnios), lung development problems, skeletal abnormalities, hypotension, renal failure, or death. Discontinue this medication immediately if pregnancy is detected. Thiazides cross the placenta and may cause fetal or neonatal jaundice and thrombocytopenia.
Breastfeeding: No data are available on the presence of telmisartan in human milk. Hydrochlorothiazide is present in human milk. Due to the potential for serious adverse reactions in a breastfed infant, including hypotension and renal impairment, breastfeeding is not recommended during treatment.
Micardis HCT may interact with the following medications or substances:
Patients should inform their healthcare provider about all substances, supplements, and medications they use before starting Micardis HCT tablets.
Other angiotensin receptor blocker (ARB) and thiazide diuretic combinations include:
| Brand Name | Active Ingredient(s) | Drug Class |
|---|---|---|
| Diovan HCT | Valsartan / Hydrochlorothiazide | ARB + Thiazide Diuretic |
| Benicar HCT | Olmesartan / Hydrochlorothiazide | ARB + Thiazide Diuretic |
| Hyzaar | Losartan / Hydrochlorothiazide | ARB + Thiazide Diuretic |
← Swipe to see more →
These medications contain different active ingredients and should not be substituted without medical guidance. Brand availability may vary by location and supply. Treatment selection should be determined by a healthcare provider based on blood pressure goals, patient-specific risk factors, potential drug interactions, and clinical response.
Prescription blood pressure medications may be costly at many U.S. retail pharmacies. Ordering Micardis HCT online from Polar Bear Meds may help reduce overall costs while maintaining safety, quality, and reliability.
All Micardis HCT orders require a valid prescription. Medications are dispensed by licensed pharmacies that comply with applicable pharmacy regulations and safety standards.
This content is for informational purposes only and does not replace expert medical guidance, diagnosis, or treatment. Micardis HCT is a prescription medication indicated for the treatment of hypertension (high blood pressure). Always consult an authorized healthcare professional before starting, stopping, or changing the dosage. Individual results, side effects, and dosing needs may vary.

Dr. Jackson Miller is a board-certified medicine physician & hospitalist. He is a healthcare professional with a strong background in patient care. With years of experience and a patient-first approach, he believes the foundation of good health is a patient who feels informed and empowered. He contributes to medical content review, drawing on his background in clinical practice and patient education. He focuses on presenting health information in a clear, accurate, and accessible way to help readers make informed decisions. His work emphasizes clarity, evidence-based guidance, and understandable explanations of medical topics.
Learn more about Micardis HCT and related topics